Evaluation of weekly tafenoquine antimalarial prophylaxis in Vietnam People’s Army personnel in South Suda

Phase 4

Withdrawn

• Conditions: Malaria; Infection - Other infectious diseases

• Registration Number: ACTRN12622000272796
• Lead Sponsor: Australian Defence Force Malaria and Infectious Disease Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-14
• Last Update Posted: 10 October 2022

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

1)Adults (male and female).
2)Glucose-6-phospate dehydrogenase (G6PD) normal enzyme activity levels (>70%) of the site median value for G6PD normals using a quantitative G6PD test.
3)Willing and able to comply with all monitoring visits, physical examination, adverse events questionnaire, laboratory tests, and other study procedures.
4)Willingness to complete an acceptability questionnaire.
5)Completion of the written informed consent process prior to undertaking any study-related procedure.

Exclusion Criteria

1)G6PD deficiency.
2)Prior or current history of nervous system and psychiatric disorders.
3)Any participant who is directly involved in conducting the study.
4)Any participant with poor peripheral venous access for blood sampling.
5)Known hypersensitivity reactions to primaquine.
6) Pregnant women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified